Search
Indomethacin
go.drugbank.com/drugs/DB00328ApprovedInvestigationalsuperficial punctate keratitis and subjective symptoms of discomfort, including pain, burning or pricking, or a tingling sensation after instillation into the cul‐de‐sac. … Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties.
Milnacipran
go.drugbank.com/drugs/DB04896ApprovedInvestigationalNevertheless, milnacipran demonstrates a somewhat unique characteristic among SNRIs to elicit a relatively balanced reuptake inhibition of both serotonin and noradrenaline, with a somewhat increased preference … Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment
Aspartyl-alanyl-diketopiperazine
go.drugbank.com/drugs/DB14940InvestigationalAspartyl-alanyl-diketopiperazine is under investigation in clinical trial NCT03349645 (An Open Label Extension Study to Assess the Safety of Long-Term Treatment With Ampion for Severe OA of the Knee).
EU204
go.drugbank.com/drugs/DB17438InvestigationalEU204 (EBViNT) is an Epstein-Barr virus (EBV)-positive T-cell therapy currently undergoing phase 1 and 2a clinical trials in Korea for patients with EBV-positive lymphoma and solid cancer.
Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone
go.drugbank.com/drugs/DB15235InvestigationalDi-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone is under investigation in clinical trial NCT02688101 (Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced
Synonyms: Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazoneTeceleukin
go.drugbank.com/drugs/DB15389InvestigationalTeceleukin is under investigation in clinical trial NCT03610490 (Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Osteosarcoma, or Pancreatic
VB10.16
go.drugbank.com/drugs/DB17512InvestigationalVB10.16 is a novel therapeutic antigen-presenting cell-targeting DNA vaccine developed to treat HPV16-positive cancers. … It is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting
Binodenoson
go.drugbank.com/drugs/DB04853InvestigationalBinodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A<sub>2A</sub> receptor. … This specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion
PN0621
go.drugbank.com/drugs/DB05218ExperimentalPN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis.
Cyclo(prolylglycyl)
go.drugbank.com/drugs/DB04541InvestigationalNA-831 (Traneurocin), is under investigation in two clinical trials: NCT03538522 (completed, for mild cognitive impairment and Alzheimer’s disease) and NCT04452565 (unknown status, combination therapy
Synonyms: (S)-Hexahydropyrrolo(1,2-a)pyrazine-1,4-dione-4-17O